ABSTRACT
Radiotherapy is a commonly used treatment for pituitary macrotumors in dogs, but the optimum protocol has not been established. Twenty four dogs with MRI confirmed pituitary macrotumors were treated with one of two radiotherapy protocols. Twelve dogs were treated with 10 fractions of 3.8 Gy/fraction on a "Monday-Wednesday-Friday" schedule, the remaining 12 with five "once-a-week" protocols (1 × 5 Gy, followed by 4 × 8.25 Gy) to a total dose of 38 Gy. The overall median survival time for all dogs was 235 days (range 28-1,328), dogs treated with 10 fractions had a median survival time of 961 days (range 28-1,328) compared to 182 days (range 42-507) in the five-fraction group (P = 0.006). Clinical improvement was found in both groups, and no significant side effects were noted in either group. These results suggest that a "Monday-Wednesday-Friday" schedule may improve survival times, as compared to a "once-a-week" protocol. As this study was of an observational nonrandomized nature, future work is necessary to establish whether more highly fractionated protocols or different total doses will further improve outcome.
Subject(s)
Adenoma/veterinary , Dog Diseases/radiotherapy , Pituitary Neoplasms/veterinary , Radiation Dosage , Adenoma/radiotherapy , Animals , Dogs , Dose Fractionation, Radiation , Female , Magnetic Resonance Imaging/veterinary , Male , Pituitary Neoplasms/radiotherapy , Time FactorsABSTRACT
A 14-year-old male neutered Burmese cat presented for investigation of right fore limb lameness that was non-responsive to anti-inflammatory drugs and opioids. Thoracic radiography showed multiple pulmonary soft tissue nodules and a larger cavitated mass. Right elbow radiographs revealed marked peri-articular proliferation of new bone and periosteal reaction primarily affecting the ulna. Histopathological examination of an incisional biopsy of the right ulna revealed neoplastic proliferation of epithelial cells; this was confirmed as a poorly differentiated carcinoma with immunohistochemistry. Amputation of the right fore limb was performed at the owner's request. After surgery, radiographs of the limb showed progression of bone proliferation. Repeat pathological analysis confirmed a metastatic carcinoma. The cat deteriorated 3 days after surgery and was euthanased a week later as a result of severe respiratory distress. This case represents an unusual case of metastasis of a suspected primary lung tumour to the ulna in a Burmese cat.
Subject(s)
Bone Neoplasms/veterinary , Carcinoma/veterinary , Cat Diseases/pathology , Lung Neoplasms/veterinary , Ulna , Animals , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/secondary , Carcinoma/diagnostic imaging , Carcinoma/secondary , Cat Diseases/diagnostic imaging , Cats , Forelimb/diagnostic imaging , Lameness, Animal/etiology , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Male , Radiography , Ulna/diagnostic imaging , Ulna/pathologyABSTRACT
BACKGROUND: Reports of canine anal sac gland carcinoma (ASGC) describe varied clinical presentations and management and differing responses to therapy. A unifying approach to clinical stage determination and management of this disease has yet to be presented. HYPOTHESIS: An ordinal clinical staging scheme for canine ASGC can be devised on the basis of responses to therapy for a retrospective cohort of affected dogs. ANIMALS: 130 dogs with naturally occurring ASGC. METHODS: A simplified clinical stage system and a management algorithm for canine ASGC were derived from retrospective evaluation of a cohort of 80 dogs; applicability of both was then prospectively evaluated in a cohort of 50 dogs. RESULTS: Retrospective evaluation revealed 4 statistically significant negative prognostic indicators for survival: lack of therapy, presence of distant metastases, presence of lymph node metastases, and primary tumor size. Lymph node extirpation was a statistically significant positive prognostic indicator by bivariate analysis. In both retrospective and prospective analyses, the modified clinical stage scheme revealed a significant association with survival time. CONCLUSIONS AND CLINICAL IMPORTANCE: The clinical staging scheme permits differentiation between groups in terms of prognosis and, therefore, decisions on therapy. This will facilitate application of appropriate therapy and enhanced communication and collaboration in further investigations of ASGC.
Subject(s)
Anal Sacs/pathology , Dog Diseases/diagnosis , Dog Diseases/therapy , Neoplasms/veterinary , Algorithms , Animals , Antineoplastic Agents/therapeutic use , Dog Diseases/classification , Dogs , Female , Male , Neoplasms/pathology , Neoplasms/therapy , Radiotherapy/veterinary , Retrospective Studies , Survival RateABSTRACT
This is the first report of feline solitary plasmacytoma of bone. We describe the clinical, clinico-pathological, radiographic and pathological findings of two successfully treated cats with long-term follow-up. The first case presented with spinal pain and neurological deficits. Radiographs demonstrated sclerosis of lumbar vertebra L6 and a myelogram confirmed interference to flow of contrast in the L4-7 region. A biopsy of L6 revealed neoplastic plasma cell infiltration. There was no evidence of paraproteinaemia on serum protein electrophoresis. The cat underwent hypofractionated megavoltage radiotherapy. Clinical signs resolved completely and 4 years after diagnosis the cat remains well and has no electrophoretically detectable paraproteinaemia. The second case presented with neurological deficits of the tail and spinal radiographs revealed extensive osteolysis of the sacrum. A biopsy of sacral bone demonstrated neoplastic plasma cell infiltration. The animal was normoglobulinaemic. The cat improved clinically with induction chemotherapy (melphalan and methylprednisolone). The same chemotherapeutics were continued at maintenance doses for 4.3 years, at which time there was recurrence of neurological deficits and a palpable sacral mass. Cytological examination of a fine needle aspirate confirmed recurrence of plasma cell neoplasia. A low concentration monoclonal paraproteinaemia was detected. Vincristine was administered resulting in resolution of neurological deficits and a palpably smaller sacral mass. Eighteen months into vincristine therapy, there was recurrence of clinical signs and the cat was euthanased, more than 6 years after the initial diagnosis.
Subject(s)
Cat Diseases/diagnosis , Cat Diseases/therapy , Plasmacytoma/veterinary , Spinal Neoplasms/veterinary , Animals , Cat Diseases/diagnostic imaging , Cat Diseases/drug therapy , Cat Diseases/pathology , Cat Diseases/radiotherapy , Cats , Combined Modality Therapy , Female , Follow-Up Studies , Male , Plasmacytoma/diagnosis , Plasmacytoma/therapy , Radiography , Spinal Neoplasms/diagnosis , Spinal Neoplasms/therapy , Treatment OutcomeABSTRACT
The responses of 15 cats with histologically (n=14) or cytologically (n=1) confirmed nasal squamous cell carcinoma treated with (90)Strontium plesiotherapy were reviewed retrospectively. Cats were treated such that a total dose of 50Gy was delivered at a depth of 2mm, administered in five fractions over a 10-day period. Of the cats, 11 were stage T(2), three were T(is) and one had only a cytological diagnosis precluding staging. Eleven of the cats achieved complete response (no visible lesion after 6-8 weeks) following the first cycle of therapy, and two cats with partial response achieved complete response with a second cycle of therapy. The remaining two cats achieved partial response following therapy, but further intervention was declined. Euthanasia was performed in these two cats because of progressive disease after 81 and 142 days. Of the 85% of cats that achieved a complete response, there was no recurrence of disease during a follow-up period of 134-2,043 days (median 652 days). In addition to prolonged disease-free survivals, (90)Strontium therapy produced excellent cosmetic results from the owners' perspective. These results demonstrate that superficial squamous cell carcinoma of the feline nasal planum responds excellently to (90)Strontium plesiotherapy, and this form of therapy may offer advantages over other alternatives currently available.